At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Indacaterol 300μg +1 moredrug
Likely dose
Indacaterol 300μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory, Double Blind, Randomized, Placebo-controlled, 2-way Cross-over Study to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With COPD
In Brief
A Phase 2 clinical trial evaluating Indacaterol 300μg and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 27 participants across 3 sites.
Detailed Summary
This study evaluated the effect of QAB149 on dynamic and static hyperinflation, breathlessness, and health status in COPD patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedMar 2008
Primary CompletionAug 2008
TodayJul 2026
First PostedMar 17, 2008
Enrollment StartFeb 1, 2008
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.3 years ago
Interventions
Indacaterol 300μgdrug
300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
Placebodrug
Matching placebo devices and hard gelatin capsules